Table 1.
Ongoing Clinical Trial With Acalabrutinib In Patients With NHL
| NCT# | Study Name | Other Drugs | NHL Subtype | Company Or IST | Sites | Active And Recruiting(Yes/No) |
|---|---|---|---|---|---|---|
| NCT02180711 | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | Lenalidomide Rituximab |
MZL FL |
Company | US | Yes |
| NCT03571308 | (ACCEPT) | R-CHOP | DLBCL | IST | UK | Yes |
| NCT03527147 | (PRISM) | AZD9150 AZD6738 Hu5F9-G4 Rituximab AZD5153 |
Aggressive NHL | Company | US and UK | Yes |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | ACP-319 | B-NHL | Company | US | No |
| NCT02362035 | (KEYNOTE145) | Pembrolizumab | NHL | Company | US | No |
| NCT02972840 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | Bendamustine Rituximab Venetoclax |
MCL | Company | Global | Yes |
| NCT03899337 | (STELLAR) | R-CHOP | DLBCL | IST | UK | No |
| NCT03863184 | Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | Lenalidomide Rituximab |
MCL | IST | US | No |
| NCT03736616 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | RICE | DLBCL | IST | US | No |
| NCT02972840 | (ECHO) | Bendamustine Rituximab |
MCL | Company | Global | Yes |
| NCT03623373 | Acalabrutinib With Alternating Cycles of Bendamustine/Rituximab and Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma | Bendamustine Cytarabine Rituximab |
MCL | IST | US | Yes |
| NCT03946878 | Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Venetoclax | MCL | IST | US | Yes |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | Vistusertib | DLBCL Richter’s |
Company | US | No |
| NCT02180724 | An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia | None | WM | Company | Global | No |
| NCT03198650 | A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies | Obinutuzumab | MCL CLL |
Company | Japan | Yes |
| NCT02112526 | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | None | DLBCL | Company | Global | No |
| NCT03932331 | Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies | None | MCL CLL |
Company | China | No |